

(43) International Publication Date
7 July 2005 (07.07.2005)

PCT

(10) International Publication Number
WO 2005/060992 A1(51) International Patent Classification⁷: A61K 38/45, 38/19, A61P 35/00, 37/02

(21) International Application Number: PCT/AU2004/001840

(22) International Filing Date: 23 December 2004 (23.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 2003907195 24 December 2003 (24.12.2003) AU

(71) Applicant (for all designated States except US): THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH [AU/AU]; 1G Royal Parade, Parkville, Victoria 3052 (AU).

(72) Inventors; and


(75) Inventors/Applicants (for US only): SHORTMAN, Ken [AU/AU]; 92 Wilson Street, Carlton North, Victoria 3054 (AU). O'KEEFFE, Meredith [AU/AU]; 10 Hudson Grove, West Brunswick, Victoria 3055 (AU). FANCKE, Ben [AU/AU]; 4 Kelvin Grove, Ashburton, Victoria 3147 (AU). HARRISON, Len [AU/AU]; 27 Park Street, St Kilda West, Victoria 3182 (AU). STEPTOE, Ray [AU/AU]; 16 Glenlyon Drive, Ashgrove, Queensland 4060 (AU). VREMEC, David [AU/AU]; 2 Brett Place, Ferntree Gully, Victoria 3156 (AU).

(74) Agents: HUGHES, E, John, L et al.; Davies Collison Cave, 1 Nicholson Street, Melbourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

[Continued on next page]

(54) Title: THERAPEUTIC AGENTS AND USES THEREFOR



(57) Abstract: The present invention relates generally to therapeutic agents and methods which enhance or otherwise maintain a state of immune tolerance in a subject. The present invention further provides agents and methods for preventing or at least delaying onset of an autoimmune disease such as but not limited to autoimmune diabetes. Furthermore, the agents and methods of the present invention are useful in enhancing the effectiveness of vaccine regimes such as against cancer cells or pathogenic organisms and viruses or for generally enhancing the immune responsiveness against such entities. The present invention further enables the prevention of pathogenic agent-induced autoimmune conditions.



KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.